Geographic Atrophy (GA), an advanced form of age-related macular degeneration (AMD), is a progressive eye condition that leads to central vision loss. Affecting over 75,000 Australians, GA has long been without an effective treatment—until now. The recent approval of **SYFOVRE® (pegcetacoplan)** marks a significant milestone in managing this debilitating condition.